319 related articles for article (PubMed ID: 26529100)
1. Emerging anti-cancer antibodies and combination therapies targeting HER3/ERBB3.
Gaborit N; Lindzen M; Yarden Y
Hum Vaccin Immunother; 2016 Mar; 12(3):576-92. PubMed ID: 26529100
[TBL] [Abstract][Full Text] [Related]
2. Combining anti-ERBB3 antibodies specific for domain I and domain III enhances the anti-tumor activity over the individual monoclonal antibodies.
D'Souza JW; Reddy S; Goldsmith LE; Shchaveleva I; Marks JD; Litwin S; Robinson MK
PLoS One; 2014; 9(11):e112376. PubMed ID: 25386657
[TBL] [Abstract][Full Text] [Related]
3. Targeting of erbB3 receptor to overcome resistance in cancer treatment.
Ma J; Lyu H; Huang J; Liu B
Mol Cancer; 2014 May; 13():105. PubMed ID: 24886126
[TBL] [Abstract][Full Text] [Related]
4. Targeting of ErbB1, ErbB2, and their Dual Targeting Using Small Molecules and Natural Peptides: Blocking EGFR Cell Signaling Pathways in Cancer: A Mini-Review.
Patnaik SK; Chandrasekar MJN; Nagarjuna P; Ramamurthi D; Swaroop AK
Mini Rev Med Chem; 2022 Oct; 22(22):2831-2846. PubMed ID: 35549881
[TBL] [Abstract][Full Text] [Related]
5. Clinical development of HER3-targeting monoclonal antibodies: Perils and progress.
Jacob W; James I; Hasmann M; Weisser M
Cancer Treat Rev; 2018 Jul; 68():111-123. PubMed ID: 29944978
[TBL] [Abstract][Full Text] [Related]
6. ERBB3 (HER3) is a key sensor in the regulation of ERBB-mediated signaling in both low and high ERBB2 (HER2) expressing cancer cells.
Choi BK; Fan X; Deng H; Zhang N; An Z
Cancer Med; 2012 Aug; 1(1):28-38. PubMed ID: 23342251
[TBL] [Abstract][Full Text] [Related]
7. An ErbB3 antibody, MM-121, is active in cancers with ligand-dependent activation.
Schoeberl B; Faber AC; Li D; Liang MC; Crosby K; Onsum M; Burenkova O; Pace E; Walton Z; Nie L; Fulgham A; Song Y; Nielsen UB; Engelman JA; Wong KK
Cancer Res; 2010 Mar; 70(6):2485-94. PubMed ID: 20215504
[TBL] [Abstract][Full Text] [Related]
8. HER3/ErbB3, an emerging cancer therapeutic target.
Zhang N; Chang Y; Rios A; An Z
Acta Biochim Biophys Sin (Shanghai); 2016 Jan; 48(1):39-48. PubMed ID: 26496898
[TBL] [Abstract][Full Text] [Related]
9. Antibody targeting of HER2/HER3 signaling overcomes heregulin-induced resistance to PI3K inhibition in prostate cancer.
Poovassery JS; Kang JC; Kim D; Ober RJ; Ward ES
Int J Cancer; 2015 Jul; 137(2):267-77. PubMed ID: 25471734
[TBL] [Abstract][Full Text] [Related]
10. Targeting ErbB2 and ErbB3 with a bispecific single-chain Fv enhances targeting selectivity and induces a therapeutic effect in vitro.
Robinson MK; Hodge KM; Horak E; Sundberg AL; Russeva M; Shaller CC; von Mehren M; Shchaveleva I; Simmons HH; Marks JD; Adams GP
Br J Cancer; 2008 Nov; 99(9):1415-25. PubMed ID: 18841159
[TBL] [Abstract][Full Text] [Related]
11. Novel anti-ErbB3 monoclonal antibodies show therapeutic efficacy in xenografted and spontaneous mouse tumors.
Aurisicchio L; Marra E; Luberto L; Carlomosti F; De Vitis C; Noto A; Gunes Z; Roscilli G; Mesiti G; Mancini R; Alimandi M; Ciliberto G
J Cell Physiol; 2012 Oct; 227(10):3381-8. PubMed ID: 22213458
[TBL] [Abstract][Full Text] [Related]
12. A Potent HER3 Monoclonal Antibody That Blocks Both Ligand-Dependent and -Independent Activities: Differential Impacts of PTEN Status on Tumor Response.
Xiao Z; Carrasco RA; Schifferli K; Kinneer K; Tammali R; Chen H; Rothstein R; Wetzel L; Yang C; Chowdhury P; Tsui P; Steiner P; Jallal B; Herbst R; Hollingsworth RE; Tice DA
Mol Cancer Ther; 2016 Apr; 15(4):689-701. PubMed ID: 26880266
[TBL] [Abstract][Full Text] [Related]
13. Irreversible multitargeted ErbB family inhibitors for therapy of lung and breast cancer.
Subramaniam D; He AR; Hwang J; Deeken J; Pishvaian M; Hartley ML; Marshall JL
Curr Cancer Drug Targets; 2015; 14(9):775-93. PubMed ID: 25435079
[TBL] [Abstract][Full Text] [Related]
14. ERBB3/HER3 and ERBB2/HER2 duet in mammary development and breast cancer.
Stern DF
J Mammary Gland Biol Neoplasia; 2008 Jun; 13(2):215-23. PubMed ID: 18454306
[TBL] [Abstract][Full Text] [Related]
15. Engineering multivalent antibodies to target heregulin-induced HER3 signaling in breast cancer cells.
Kang JC; Poovassery JS; Bansal P; You S; Manjarres IM; Ober RJ; Ward ES
MAbs; 2014; 6(2):340-53. PubMed ID: 24492289
[TBL] [Abstract][Full Text] [Related]
16. Esophageal Adenocarcinoma Cells and Xenograft Tumors Exposed to Erb-b2 Receptor Tyrosine Kinase 2 and 3 Inhibitors Activate Transforming Growth Factor Beta Signaling, Which Induces Epithelial to Mesenchymal Transition.
Ebbing EA; Steins A; Fessler E; Stathi P; Lesterhuis WJ; Krishnadath KK; Vermeulen L; Medema JP; Bijlsma MF; van Laarhoven HWM
Gastroenterology; 2017 Jul; 153(1):63-76.e14. PubMed ID: 28286209
[TBL] [Abstract][Full Text] [Related]
17. Altered binding avidities and improved growth inhibitory effects of novel anti-HER3 mAb against human cancers in the presence of HER1-or HER2-targeted drugs.
Okita K; Imai K; Kato K; Sugiura R; Endo Y; Masuko K; Tomioka Y; Masuko T
Biochem Biophys Res Commun; 2021 Oct; 576():59-65. PubMed ID: 34482024
[TBL] [Abstract][Full Text] [Related]
18. The anti-erbB3 antibody MM-121/SAR256212 in combination with trastuzumab exerts potent antitumor activity against trastuzumab-resistant breast cancer cells.
Huang J; Wang S; Lyu H; Cai B; Yang X; Wang J; Liu B
Mol Cancer; 2013 Nov; 12(1):134. PubMed ID: 24215614
[TBL] [Abstract][Full Text] [Related]
19. Combination therapy with anti-ErbB3 monoclonal antibodies and EGFR TKIs potently inhibits non-small cell lung cancer.
Noto A; De Vitis C; Roscilli G; Fattore L; Malpicci D; Marra E; Luberto L; D'Andrilli A; Coluccia P; Giovagnoli MR; Normanno N; Ruco L; Aurisicchio L; Mancini R; Ciliberto G
Oncotarget; 2013 Aug; 4(8):1253-65. PubMed ID: 23896512
[TBL] [Abstract][Full Text] [Related]
20. Signaling via ErbB2 and ErbB3 associates with resistance and epidermal growth factor receptor (EGFR) amplification with sensitivity to EGFR inhibitor gefitinib in head and neck squamous cell carcinoma cells.
Erjala K; Sundvall M; Junttila TT; Zhang N; Savisalo M; Mali P; Kulmala J; Pulkkinen J; Grenman R; Elenius K
Clin Cancer Res; 2006 Jul; 12(13):4103-11. PubMed ID: 16818711
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
